1. Scope

– Covered: Oral supplementation with synthetic urolithin A (UA; the branded pharmaceutical-grade form is Mitopure) as an adjunctive, mitophagy-directed intervention in a private UK longevity setting. Covers biological rationale, human evidence, patient selection, dosing, monitoring and practical management. UA is a gut-microbiota metabolite of dietary ellagitannins/ellagic acid (pomegranate, walnuts, berries); direct supplementation bypasses the need for the “urolithin-producing” microbiome, which is absent in a large proportion of people (UA was detectable in the plasma of only ~12% of screened healthy adults).[1]

– Not covered: Ellagitannin-rich foods/pomegranate extracts as such, other urolithin isomers (B, C, methylated forms), disease-specific treatment of established sarcopenia, neurodegenerative disease or cardiac disease (no robust human outcome data), and paediatric use.

– Positioning: All use for “longevity” or healthspan is off-label/nutraceutical and adjunctive to conventional care. UA is not a licensed medicine; there is no MHRA/EMA marketing authorisation for any therapeutic indication.

2. Background and pathophysiology

– Rationale: Mitochondrial dysfunction and impaired mitophagy are recognised hallmarks of ageing. UA is the most-studied pharmacological mitophagy inducer, acting principally via PINK1/Parkin-mediated clearance of damaged mitochondria, coupled with mitochondrial biogenesis (PGC-1α/SIRT1-associated signalling).[1][2][3]

– Robust human mechanistic evidence: In older adults, 28 days of UA (500/1000 mg) produced dose-dependent upregulation of mitochondrial, autophagy/mitophagy and fatty-acid-oxidation genes in vastus lateralis, and lowered plasma acylcarnitines and inflammatory markers (CRP, cytokines) — i.e. demonstrated target engagement at the muscle and systemic level. UA is bioavailable at 250–2000 mg, has a long half-life (t½ ≈ 17–22 h) and is detectable in skeletal muscle.[1][4]

The following figure from the first-in-human study (Andreux et al., Nature Metabolism 2019) shows the dose-dependent muscle mitochondrial gene-expression signature, which mirrors the difference between active and pre-frail elderly individuals:

Figure 2 UA impacts markers of mitochondrial function after 28 d of treatment. a, Comparison of mRNA levels of autophagy/mitophagy, mitochondrial biogenesis and fatty acid oxidation markers as measured by qPCR in vastus lateralis of subjects who received placebo, UA 500 or 1,000 mg for 28 d (n = 9 biologically independent samples). Results are expressed as a ratio over the placebo group for better readability. b, Change in mitochondrial abundance as measured by qPCR in vastus lateralis skeletal muscle of subjects who received placebo, UA 500 or 1,000 mg for 28 d (n = 9 biologically independent samples). All data are means ± s.e.m. # 0.05 < P < 0.15; * P < 0.05; ** P < 0.01; *** P < 0.001 after a one-way ANOVA followed by Dunnett’s post-hoc test (a, b). c, Graphical representation of GSEA results. Bars represent the normalized enrichment score for the mitochondrial gene sets that are significantly upregulated with FDR < 0.1 in the vastus lateralis skeletal muscle of subjects following UA treatment at 500 mg and 1,000 mg for 28 d compared with placebo. FDR is the estimated probability that a gene set with a given enrichment score (normalized for gene set size) represents a false positive finding. The first three gene sets are upregulated by both UA 500 mg and 1,000 mg, and the others are upregulated by 1,000 mg with the 500 mg being not significant (NS; FDR > 0.1). Mb: membrane. d, e, Genes within the GO_MITOCHONDRION gene set that are upregulated (see Methods) in vastus lateralis skeletal muscle of subjects following UA treatment at 500 or 1,000 mg for 28 d compared with placebo (c, n = 9) and in the vastus lateralis skeletal muscle of pre-frail sedentary or active healthy elderly individuals (NCT02472340) (d, n = 11). Heat map represents change in expression over time (day 28 versus pre-dose) (c) or as difference between active healthy and sedentary pre-frail (d) as Z scores. Related to Tables 1 and 2.

– Preclinical only (mechanistic plausibility, not human-proven): 45% lifespan extension and improved mobility in C. elegans; improved running endurance/grip strength in aged rodents; cardioprotection (reduced infarct size, attenuated diastolic dysfunction), haematopoietic/immune rejuvenation, and prevention of cognitive decline/tau pathology in mouse models. These are animal/in-vitro data and do not establish human clinical benefit.[5][6][7][8][9][10][11]

3. Evidence base and grading

Human data comprise a small number of RCTs (28-day and 4-month, doses 10–1000 mg/day) and one systematic review (5 studies, ~250 healthy participants). No RCT has evaluated hard clinical endpoints (mortality, incident sarcopenia, fractures, MACE, dementia). No prospective cohort links UA supplementation to disease outcomes.

Outcome	Evidence & GRADE certainty	Strength of recommendation	Notes
Safety / tolerability (≤4 months, ≤2000 mg)	Moderate — consistent across RCTs (~250 subjects); no serious AEs, no lab/vital abnormalities; NOAEL high in animal tox[12], [13], [14]	Conditional (favourable)	Long-term (>4 months) safety unknown
Muscle mitochondrial biomarkers (gene expression, acylcarnitines, CRP)	Moderate — reproducible target engagement[1], [4]	Conditional to use as a mechanistic marker	Surrogate; not validated against clinical outcomes
Muscle endurance / strength	Low — improvements seen but inconsistent; 6-min walk & max ATP non-significant vs placebo in the older-adult RCT (high placebo effect)[12], [13]	Conditional / only in selected patients	Effect clearest in those with low baseline mitochondrial function
Whole-body physical function (6MWD, VO₂peak)	Low / Very low — heterogeneous, several null results[12], [13]	Conditional / research	Underpowered, short duration
Cardiovascular, metabolic, anthropometric outcomes	Very low — no effect in humans to date[13]	Recommend against claiming benefit	Human evidence null
Cognitive / neuroprotective outcomes	Very low — no completed human trials; preclinical only[11], [15], [16]	Only in research	Do not offer for cognition
Mortality / longevity / healthspan	No human evidence	Only in research	Extrapolation from model organisms only

– GRADE downgrading factors: small samples (imprecision), short follow-up and healthy/narrow populations (indirectness to frail/comorbid longevity patients), heterogeneity between trials (inconsistency), industry sponsorship of most trials and a small literature (potential publication/reporting bias). Risk of bias is otherwise low (blinded, placebo-controlled).

4. Patient selection and indications

– Who might reasonably be considered (adjunctive, with informed consent):

– Middle-aged to older adults with sub-optimal muscle mitochondrial function / declining physical performance (e.g. reduced 6-min walk distance, reduced endurance) — the group in whom target engagement and endurance signals are strongest.[1][12]

– Individuals seeking a well-tolerated adjunct to exercise and protein optimisation for muscle healthspan, who understand the surrogate-level nature of the evidence.

– Unlikely to benefit: individuals with already high physical performance/mitochondrial function (large placebo effect, no incremental benefit demonstrated).[12]

– Not evidence-supported (avoid promising benefit): cardiometabolic risk reduction, weight loss, cognitive enhancement, athletic performance in already highly-trained individuals (evidence lacking/under study).[13][17]

– Exclusion / caution groups: pregnancy and breastfeeding (no data), significant hepatic or renal impairment (no dedicated PK/safety data), active malignancy (UA modulates p53/MDM2 and proliferation pathways in vitro — mechanistic uncertainty), and children.

– Regulatory/ethical status: UA has US FDA GRAS status as a food ingredient (GRN 000791, up to ~1000 mg/serving) and an EFSA novel-food application; it is not a licensed medicine. UK use is as an unlicensed food supplement, off-label for any longevity indication — document informed consent covering the experimental/surrogate nature of benefit.[18][19]

5. Assessment and baseline work-up

– History and examination: medication and supplement review, comorbidities, falls/frailty, nutrition and protein intake, physical activity. Screen for pregnancy, hepatic/renal disease, active cancer.

– Functional baseline (to allow meaningful follow-up): validated measures such as gait speed, grip strength, chair-rise, 6-minute walk distance; consider a frailty/sarcopenia screen (e.g. SARC-F) in older adults.

– Baseline bloods: FBC, renal profile, LFTs, HbA1c/lipids and hs-CRP (inflammatory marker plausibly responsive to UA). These support safety monitoring rather than proof of efficacy.[1]

– Risk stratification: low risk = healthy middle-aged/older adult on no interacting therapy; moderate = polypharmacy, frailty, mild organ impairment (specialist/GP liaison advised); high = pregnancy, significant hepatic/renal disease, active malignancy (avoid).

– Documentation: baseline functional scores, weight/BMI, hs-CRP and LFT/renal values, indication, consent, and dose — so that response and safety can be tracked.

6. Dosing regimens and practical implementation

– Best-supported human regimen: 500–1000 mg once daily orally with food, continued for at least 4 months to reach the durations used in RCTs demonstrating biomarker and endurance effects. 1000 mg/day gave the fullest mitochondrial gene signature at 28 days.[1][12][4]

– Titration: no formal titration required; a single fixed daily dose is used. No loading dose. Dose–response is evident for biomarkers (500 < 1000 mg), but not established for clinical outcomes.[4]

– Upper exposure: doses up to 2000–2500 mg/day have been tested short-term without clinical/laboratory abnormality, but there is no benefit rationale to exceed 1000 mg/day.[18][9]

– Adjuncts (foundational, higher-certainty than UA itself): resistance/aerobic exercise and adequate dietary protein remain the evidence-based core of muscle healthspan; UA should be framed as a possible adjunct, not a substitute.[1]

– Caution — extrapolated regimens: any dosing aimed at cardiac, cognitive, immune or “lifespan” endpoints is extrapolated from preclinical data and should be regarded as experimental.[5][6][15]

7. Monitoring, safety and follow-up

– Safety profile: across RCTs UA was safe and well tolerated, with only mild–moderate adverse events (predominantly GI, e.g. loose stools, diarrhoea, nausea), no excess over placebo, and no serious adverse events or clinically significant lab/vital changes up to 2000 mg. Animal toxicology showed no genotoxicity and a high NOAEL.[12][13][18][14]

– Monitoring plan:

– Clinical: GI tolerance and functional response at ~3 months.

– Laboratory: repeat LFTs and renal profile and hs-CRP at ~3–4 months if baseline abnormal or if on interacting/hepatically-cleared drugs; otherwise routine annual review.

– Functional/ageing markers: repeat gait speed/grip/6MWD at 4 months to judge whether continuation is justified.

– Timepoints: review at ~4 weeks (tolerance), 3–4 months (efficacy and safety re-assessment), then 6–12-monthly if continued.

– Action on abnormal findings: stop for any significant unexplained LFT/renal derangement or persistent GI intolerance; reassess indication if no functional benefit by 4 months.

– Interactions: no clinically characterised drug–drug interactions in humans; UA is glucuronidated/sulfated, so theoretical interactions via phase II metabolism are unquantified — exercise caution with narrow-therapeutic-index drugs and document.

– Special populations: avoid in pregnancy and breastfeeding (no data); use only with specialist input in hepatic/renal impairment and in frail multimorbid patients; no dedicated data in extreme old age beyond the ≤90-year trial population.[12]

8. Contraindications and cautions

– Absolute: known hypersensitivity; pregnancy and breastfeeding (precautionary, no data).

– Relative / specialist advice advised: significant hepatic or renal impairment; active or recent malignancy (mechanistic uncertainty around p53/MDM2 and proliferative pathways in vitro); complex polypharmacy; frailty with multimorbidity.[9]

– Harm likely to outweigh benefit with current evidence: any use marketed as disease treatment or life-extension, or use displacing evidence-based care (exercise, protein, cardiometabolic risk management).

9. Practical management scenarios

Scenario A — Middle-aged patient with multiple cardiometabolic risk factors requesting UA.

– Recommendation: Consider, but do not offer for cardiometabolic benefit (Conditional; against for CV indication). Human data show no cardiovascular or metabolic benefit.[13]

– Assessment: cardiometabolic risk work-up and guideline-based management (statin, BP, glycaemia, lifestyle) are the priority. Consent: clarify UA does not treat CV risk; any use is for general muscle/mitochondrial healthspan only. Initiation: if the patient still wishes, 500–1000 mg/day with food as an adjunct to exercise. Monitor: tolerance at 4 weeks, function/hs-CRP at 4 months. Escalate/stop: ensure UA never displaces proven CV risk reduction; stop if no functional benefit.

Scenario B — Older, frail, multimorbid patient.

– Recommendation: Restrict to carefully selected cases / consider only with GP–geriatric liaison (Conditional, cautious). Trial populations were relatively healthy older adults, aged up to 90; frail multimorbid patients are under-represented (indirectness).[12]

– Assessment: frailty/sarcopenia and falls assessment, medication review, LFT/renal baseline. Consent: emphasise low-certainty evidence and unknown long-term safety. Initiation: exercise + protein first; if adding UA, start 500 mg/day. Monitor: closer review (4 weeks, 3 months) for GI tolerance and hydration (diarrhoea risk). Stop if intolerant, if polypharmacy concerns arise, or if no functional gain by 4 months.

Scenario C — Patient under specialist care wanting UA as an adjunct (e.g. cardiology, neurology, oncology follow-up).

– Recommendation: Only with the treating specialist’s agreement; only in research for neuro/oncology indications. For any neurodegenerative or cardiac disease-modifying goal, human evidence is absent — only in research.[6][15]

– Assessment/decision: liaise with the specialist; screen for active malignancy and hepatic/renal issues. Consent: document that UA is adjunctive, unlicensed and not disease-modifying. Initiation/monitoring: 500–1000 mg/day with specialist awareness; shared monitoring of relevant labs. Escalate/stop: stop for any new safety signal or if it complicates the primary treatment.

10. Research gaps and future directions

– Hard outcomes: no RCT has tested incident sarcopenia, falls/fractures, MACE, dementia, disability or mortality — the surrogate-to-outcome link remains unproven.

– Population/effect modifiers: need for adequately powered trials selecting patients with genuinely low baseline mitochondrial function or frailty, and clarification of the role of urolithin metabotype (UM-A/B/0) status.[20][19]

– Duration & dose–response for clinical (not biomarker) endpoints, and combination with structured exercise (mechanistically complementary, formally untested).[12][1]

– Under-studied domains in humans: cardiovascular, cognitive/CNS (no completed trials despite strong preclinical rationale), immune ageing, and long-term (>4 months) safety.[6][15][7]

– Where practice should stay within trials/registries: all cardiac, neurodegenerative, oncological and “lifespan-extension” uses. Longevity-clinic use is best captured in a prospective registry with standardised functional and biomarker endpoints and adverse-event capture.


References

1. Mitochondria as Nutritional Targets to Maintain Muscle Health and Physical Function During Ageing. Broome SC, Whitfield J, Karagounis LG, Hawley JA. Sports Medicine (Auckland, N.Z.). 2024;54(9):2291-2309. doi:10.1007/s40279-024-02072-7.
2. Impact of the Natural Compound Urolithin a on Health, Disease, and Aging. D’Amico D, Andreux PA, Valdés P, et al. Trends in Molecular Medicine. 2021;27(7):687-699. doi:10.1016/j.molmed.2021.04.009.
3. Distinct Roles of Urolithin a and Spermidine in Mitophagy and Autophagy: Implications for Dietary Supplementation. Borsky P, Holmannova D, Soukup O, et al. Nutrition Research Reviews. 2025;39:e8. doi:10.1017/S0954422425100292.
4. The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans. Andreux PA, Blanco-Bose W, Ryu D, et al. Nature Metabolism. 2019;1(6):595-603. doi:10.1038/s42255-019-0073-4.
5. Urolithin a Modulates Inter-Organellar Communication via Calcium-Dependent Mitophagy to Promote Healthy Ageing. Roussos A, Kitopoulou K, Borbolis F, et al. Autophagy. 2025;. doi:10.1080/15548627.2025.2561073.
6. Mitochondrial quality control in cardiomyocytes: safeguarding the heart against disease and ageing. Ravindran R, Gustafsson ÅB. Nature Reviews. Cardiology. 2025;22(10):798-813. doi:10.1038/s41569-025-01142-1.
7. Induction of mitochondrial recycling reverts age-associated decline of the hematopoietic and immune systems. Girotra M, Chiang YH, Charmoy M, et al. Nature Aging. 2023;3(9):1057-1066. doi:10.1038/s43587-023-00473-3.
8. Urolithin A induces mitophagy and prolongs lifespan in C. elegans and increases muscle function in rodents. Ryu D, Mouchiroud L, Andreux PA, et al. Nature Medicine. 2016;22(8):879-88. doi:10.1038/nm.4132.
9. A mechanistic insight into the biological activities of urolithins as gut microbial metabolites of ellagitannins. Hasheminezhad SH, Boozari M, Iranshahi M, et al. Phytotherapy Research : PTR. 2022;36(1):112-146. doi:10.1002/ptr.7290.
10. Methylated Urolithin A, Mitigates Cognitive Impairment by Inhibiting NLRP3 Inflammasome and Ameliorating Mitochondrial Dysfunction in Aging Mice. Chen P, Wang Y, Xie J, Lei J, Zhou B. Neuropharmacology. 2024;252:109950. doi:10.1016/j.neuropharm.2024.109950.
11. Early mitophagy activation by Urolithin A prevents, but late activation does not reverse, age-related cognitive impairment. Jara C, Venegas-Zamora L, Park-Kang HS, et al. NPJ Aging. 2026;12(1):54. doi:10.1038/s41514-026-00351-3.
12. Effect of Urolithin A Supplementation on Muscle Endurance and Mitochondrial Health in Older Adults: A Randomized Clinical Trial. Liu S, D’Amico D, Shankland E, et al. JAMA Network Open. 2022;5(1):e2144279. doi:10.1001/jamanetworkopen.2021.44279.
13. Targeting Aging With Urolithin a in Humans: A Systematic Review. Kuerec AH, Lim XK, Khoo AL, et al. Ageing Research Reviews. 2024;100:102406. doi:10.1016/j.arr.2024.102406.
14. Safety Assessment of Urolithin A, a Metabolite Produced by the Human Gut Microbiota Upon Dietary Intake of Plant Derived Ellagitannins and Ellagic Acid. Heilman J, Andreux P, Tran N, Rinsch C, Blanco-Bose W. Food and Chemical Toxicology : An International Journal Published for the British Industrial Biological Research Association. 2017;108(Pt A):289-297. doi:10.1016/j.fct.2017.07.050.
15. Is Urolithin A(UA) a Pharmacologically Credible Neuro-Nutraceutical? A Critical Review of Mechanisms, Brain Exposure, and Evidence Gaps in Alzheimer’s and Parkinson’s Disease. Girish Oswal D, Rane M. Neurochemistry International. 2026;199:106224. doi:10.1016/j.neuint.2026.106224.
16. Mechanistic Insights Into the Neuroprotective Potential of Gut Microbiota-Derived Urolithins in Alzheimer’s Disease. Alami M, Berrougui H, Morvaridzadeh M, et al. Mechanisms of Ageing and Development. 2026;231:112189. doi:10.1016/j.mad.2026.112189.
17. Evaluating the Impact of Urolithin A Supplementation on Running Performance, Recovery, and Mitochondrial Biomarkers in Highly Trained Male Distance Runners. Whitfield J, McKay AKA, Tee N, et al. Sports Medicine (Auckland, N.Z.). 2025;55(12):3183-3200. doi:10.1007/s40279-025-02292-5.
18. Ellagic Acid‐Derived Urolithins as Modulators of Oxidative Stress. Djedjibegovic J, Marjanovic A, Panieri E, Saso L. Oxidative Medicine and Cellular Longevity. 2020;2020:5194508. doi:10.1155/2020/5194508.
19. Gut Bacteria Involved in Ellagic Acid Metabolism To Yield Human Urolithin Metabotypes Revealed. Iglesias-Aguirre CE, García-Villalba R, Beltrán D, et al. Journal of Agricultural and Food Chemistry. 2023;71(9):4029-4035. doi:10.1021/acs.jafc.2c08889.
20. Urolithins: A Comprehensive Update on Their Metabolism, Bioactivity, and Associated Gut Microbiota. García-Villalba R, Giménez-Bastida JA, Cortés-Martín A, et al. Molecular Nutrition & Food Research. 2022;66(21):e2101019. doi:10.1002/mnfr.202101019.